Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Alectinib - Usual
Alectinib- Usual · 1 trial · 1 indication
* Recruit 300 double blind random group separated NSCLC patients currently using the Chemotherapy NDC...01 on ALECENSA - alectinib 600 mg orally twice daily, after biopsy diagnosis, to be the usual approach group. * Recruit 300 double blind random group separated NSCLC patients currently using the Chemotherapy NDC...86 on ALECENSA - alectinib 600 mg orally twice daily, after biopsy diagnosis, to be the study approach group. * Measure above every NSCLC patient-specific Alectinib drug target (ALK) SNP genotype in his or her WBC cell whole genome DNA with Oxford precisely sequencing. * Report every NSCLC patient-specific ALK SNP genotype in whole genome DNA sequence. * Measure above every NSCLC patient-specific Alectinib drug target (CYP4503A4) SNP genotype in his or her WBC cell whole genome DNA with Oxford precisely sequencing. * Report every NSCLC patient-specific CYP4503A4 SNP genotype in whole genome DNA sequence.
| Arm | Type | Description |
|---|---|---|
| Alectinib - Usual | EXPERIMENTAL | * Usual ALECENSA - Alectinib * Chemotherapy (NDC...01) * Usual ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily * Usual Approach Group (NDC...01) * ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily |
| Alectinib - Study | EXPERIMENTAL | * Study ALECENSA - Alectinib * Chemotherapy (NDC...86) * Study ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily * Study Approach Group (NDC...86) * ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily |
| Name | Type | Description |
|---|---|---|
| Alectinib - Usual | DRUG | Usual Alectinib Chemotherapy (NDC...01) \- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily |
| Alectinib - Study | DRUG | Study Alectinib Chemotherapy (NDC...86) \- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily |
* Select 600 Non-Small Cell Lung Cancer Patients who are suitable for blood-drawing. * Dosage Duration at least 90 days * The usual approach group - Recruit 300 double blind random group separated NSCLC patients currently used the Chemotherapy NDC...01 on ALECENSA - alectinib hydrochloride capsule 6...
Top 20 of 84 competitors
Alectinib - Usual is an investigational small molecule being studied for the treatment of Non-small Cell Lung Cancer. It is currently in Phase 2 clinical development and has not been approved by the FDA. The drug is being evaluated in a controlled, randomized, double-blind clinical trial.
Alectinib - Usual belongs to the -tinib class of kinase inhibitors, meaning it targets kinases, enzymes that regulate cellular signaling. By inhibiting these kinases, the drug aims to interfere with cancer cell growth and survival in Non-small Cell Lung Cancer.
Alectinib - Usual is being developed by Design Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker DSGN. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Non-small Cell Lung Cancer.
Alectinib - Usual is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received FDA approval. The ongoing Phase 2 trial is active but not recruiting participants, with an enrollment target of 600 patients.
Alectinib - Usual is being studied in one active Phase 2 clinical trial with the identifier NCT05987956. The trial is titled 'Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms' and is being conducted in the United States with 600 participants.
Yes, Alectinib - Usual is also known as Alectinib. The drug is being developed under the name Alectinib - Usual, but it is the same compound. This alternative name is used in clinical trial registrations and research documentation.